Recent Updates — HYFT
MindWalk Holdings Corp. reported fiscal first quarter 2027 results ending July 31, 2026, showing revenue growth of 21.3% to $3.8 million and gross margin expansion to 58.6%. The company commercially launched its ReefIQ™ data platform in June, shifting focus toward recurring enterprise revenue. Net loss from continuing operations widened to $6.1 million ($0.13 per share) due to increased sales and marketing investments for the ReefIQ rollout. Subsequent to quarter-end, MindWalk secured a binding commitment for a US$30 million senior unsecured revolving credit facility at 7.00% interest, featuring no covenants or dilution. MindWalk Holdings Corp. operates in the biotechnology and artificial intelligence industry, providing bio-native AI infrastructure and data platforms for drug discovery.
MindWalk Holdings Corp. reported unaudited financial results for the quarter ended July 31, 2026. Revenue increased 21.3% to CAD $3.8 million from CAD $3.2 million in the prior year period, driven by a 22.6% rise in project revenue. Gross profit grew 47.1% to CAD $2.2 million with a gross margin of 59%. Operating expenses rose to CAD $8.4 million due to increased sales and marketing costs and share-based payments, resulting in a net loss from continuing operations of CAD $6.1 million compared to CAD $4.1 million previously. Cash on hand decreased to CAD $7.8 million from CAD $11.5 million at the end of April 2026. The company disclosed material uncertainty regarding its ability to continue as a going concern, stating current cash is insufficient to fund operations for at least one year without additional financing. MindWalk Holdings Corp. operates in the biotechnology and artificial intelligence industry, developing AI-driven drug discovery platforms and therapeutic candidates.
MindWalk Holdings Corp. announced a binding commitment for a US$30 million senior unsecured revolving credit facility with Sanabil (Cayman). The facility carries a fixed annual interest rate of 7.00%, accruing only on drawn amounts, and has an initial term of 36 months extendable by 12 months. It includes no financial maintenance covenants, warrants, or equity conversion features, requiring no pledge of assets. A one-time 1.00% opening fee applies with no unused line fee. MindWalk expects to close the definitive agreement within 60 days. The proceeds will fund biologics programs, commercial expansion, working capital, and general corporate purposes. This debt financing avoids equity dilution at current share prices. MindWalk Holdings Corp. is a Bio-Native AI company building biological intelligence infrastructure for life sciences discovery.